Press Releases
Q3 2015 Earnings Release
Sun BioPharma Files Form 10-Q for Third Quarter 2015 and Provides Business Update
Compelling Preclinical Data on Sun BioPharma’s SBP-101 Presented at APA Annual Meeting
Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association (APA) Annual Meeting
Presentations to Focus on Pre-Clinical Data for Company’s Lead Development Candidate, SBP-101, for the Treatment of Pancreatic Diseases
Scott Kellen Appointed Chief Financial Officer of Sun BioPharma
Healthcare Executive Brings Extensive Public Company Financial Experience to Leadership Team
J. Robert Paulson and Jeffrey Mathiesen Appointed to Board of Directors
Two Experienced Healthcare Executives Join Board as Company Prepares to Enroll First Patient in Phase 1 Clinical Trial
David Kaysen Named President & CEO of Sun BioPharma
Healthcare Executive Brings Extensive Clinical & Public Markets Experience to Sun’s Management Team
Sun BioPharma Adopts OTCPink Symbol SNBP
Company’s clinical development program focuses on novel approach to treatment of pancreatic cancer
U.S. FDA Grants IND for SBP-101
Phase 1 Clinical Study Expected to Begin By End of Year
APA 2015
Sun BioPharma will participate in the poster session at the American Pancreatic Association Annual Meeting on 4-7 November, 2015 in San Diego, CA.
For more information please visit their website at www.american-pancreatic-association.org
PancreasFest 2015
Sun BioPharma participated in the poster session at PancreasFest on 22-24 July 2015 in Pittsburgh, PA.
A joint meeting of physicians and scientists committed to learning and collaborating on translational studies of pancreatic diseases.
For more information, please visit their website at pancreasfest.com